Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
Molecular Genetics and Metabolism Reports(2022)
摘要
Elagolix is an FDA-approved treatment for moderate-to-severe pain associated with endometriosis but has been associated with increased acute porphyric attacks in women with the acute hepatic porphyrias (AHPs). A fluorescence-based screening assay for drug porphyrogenicity in LMH cells indicates that elagolix is porphyrogenic; thus, elagolix should be avoided or used with caution in patients with the AHPs.
更多查看译文
关键词
Acute hepatic porphyrias,Elagolix,Porphyrogenic,Endometriosis,OBGYN,Hepatology,Gastroenterology,Fluorescence-based screening assay,Acute porphyric attack
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要